Biovalley > Human CD45/LCA Antibody : APC
Human CD45/LCA Antibody : APC
Référence OASB01107
Conditionnement : 100tests
Marque : Aviva Systems Biology
Bulk
Order
Order
Aviva's
Satisfaction
Guarantee
Satisfaction
Guarantee
Contact Us:
- Toll Free: 888-880-0001
- Phone: 858-552-6979
- Email: info@avivasysbio.com
Shipping Info:
- : Antibody & Protein in US
- + /Kit in US
- Contact us for international orders.
Human CD45/LCA Antibody : APC (OASB01107)
| Datasheets/Manuals | Printable datasheet for Human CD45/LCA Antibody : APC (OASB01107) |
|---|
| Tested Species Reactivity | Human |
|---|---|
| Predicted Species Reactivity | Human |
| Clonality | Monoclonal |
| Clone | F10-89-4 |
| Isotype | IgG2a |
| Host | Mouse |
| Conjugation | APC |
| Application | FC |
| Additional Information | Description: CD45, also known as the leukocyte common antigen (LCA), exists as four different isoforms (180, 190, 205, 220 kDa) that are generated by alternative splicing of three exons. LCA is found on all cells of hematopoietic origin, except erythrocytes and platelets. CD45 expression is required for T cell and B cell antigen receptor-mediated activation. |
| Reconstitution and Storage | Store at 2-8C |
| Immunogen | Purified T cells from human lymph nodes |
| Concentration | Lot specific |
| Specificity | CD45 |
| Characterization | To insure lot- to- lot consistency, each batch of product is tested by flow cytometry to conform tocharacteristics of a standard reference reagent. |
| Warning | Reagents contain sodium azide which is very toxic if ingested or inhaled. Avoid contact with skin, eyes, orclothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copiousamounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxichydrazoic acid under acidic conditions. Dilute azide- containing compounds in running water beforediscarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing. |
| Dilution | Flow Cytometry: Purified (UNLB) antibody Fluorescein conjugate Biotin conjugate R-phycoerythrin conjugate Allophycocyanin conjugate Spectral Red conjugate Cyanine 5 conjugate R-phycoerythrin-Cyanine 5.5 conjugate R-phycoerythrin-Cyanine 7 conjugate <= 1 ug/106 cells 10 uL/106 cells 10 uL/106 cells 10 uL/106 cells 10 uL/106 cells 10 uL/106 cells 10 uL/106 cells 10 uL/106 cells 10 uL/106 cells |
| Application Info | Flow cytometry, Immunohistochemistry (frozen sections), Immunoprecipitation, Western blotting |
| Other Applications Data | Since applications vary, you should determine the optimum workingdilution of the product that is appropriate for your specific need. |
| Storage | - The purified (UNLB) antibody is supplied as 0.1 mg of purified immunoglobulin in 1.0 mL of 100 mMborate buffered saline, pH 8.0. No preservatives or amine- containing buffer salts added. Store at 2- 8 C - The fluorescein (FITC) conjugate is supplied as 100 tests in 1.0 mL of PBS/NaN3. Store at 2- 8 C - The biotin (BIOT) conjugate is supplied as 100 tests in 1.0 mL of PBS/NaN3. Store at 2- 8 C - The R- phycoerythrin (R- PE) and Allophycocyanin conjugates are supplied as 100 tests in 1.0 mL ofPBS/NaN3 and a stabilizing agent. Store at 2- 8 C. Do not freeze! - The Spectral Red (SPRD), R- phycoerythrin- Cyanine 5.5 (R- PE- CY 5.5), and R- phycoerythrin- Cyanine 7 (R- PE- CY 7) conjugates are supplied as 100 tests in 1.0 mL of PBS/NaN3 and a stabilizingagent. Store at 2- 8 C. Do not freeze! - The Cyanine 5 (CY 5) conjugate is supplied as 100 tests in 1.0 mL of PBS/NaN3. Store at 2- 8 C - Protect conjugated forms from light. Reagents are stable for the period shown on the label if stored asdirected. |
| Reference | 1. McMichael, A.K., P.C.L. Beverly, S. Cobbold, M.J. Crumpton, W. Gilks, F.M. Gotch, N. Hogg, M. Horton, N. Ling, I.C.M. MacLennan, D.Y Mason, C. Milstein, D. Spiegelhalter, and H. Waldmann, eds. 1987. Leukocyte Typing III: White Cell Differentiation Antigens, OxfordUniversity Press, Oxford 2. Barclay, A.N., M.H. Brown, S.K.A. Law, A.J. McKnight, M.G. Tomlinson, and P.A. van der Merwe, eds. 1997. The Leukocyte AntigensFacts Book, 2nd Edition, CD45 Section, Academic Press, New York, p. 244 3. Dalchau, R., J. Kirkley, and J.W. Fabre. Eur. J. Immunol. 10:737 4. Thomas, M.L. 1989. Annu. Rev. Immunol. 7:339 5. Trowbridge, I.S., and M.L. Thomas. 1994. Annu. Rev. Immunol. 12:85. |
|---|---|
| Gene Symbol | PTPRC |
| Gene Full Name | Receptor-type tyrosine-protein phosphatase C |
| Alias Symbols | LCA, LY5, B220, CD45, L-CA, T200, CD45R, GP180 |
| NCBI Gene Id | 5788; 100061950 |
| Protein Name | receptor-type tyrosine-protein phosphatase C |
| Description of Target | The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitosis, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus is classified as a receptor type PTP. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. |
| Uniprot ID | P08575, F6WER3 |
| Protein Accession # | NP_002829.3 |
| Nucleotide Accession # | NM_002838.4 |
Protein interactions
| Name | # of Products |
|---|---|
| ANP32A | 89 |
| C | 150 |
| CD1D | 104 |
| CD2 | 157 |
| CD247 | 234 |
| CD28 | 117 |
| CD4 | 497 |
| CD8A | 170 |
| CSNK2A1 | 551 |
| CSNK2A2 | 274 |
| CXCR4 | 126 |
| DPP4 | 131 |
| EZR | 276 |
| FCGR3A | 132 |
| FYN | 597 |
| GANAB | 68 |
| GRB2 | 1020 |
| IFNAR1 | 93 |
| INSR | 215 |
| IRS1 | 138 |
| ITGAL | 131 |
| JAK1 | 208 |
| JAK2 | 257 |
| JAK3 | 169 |
| LCK | 537 |
| LCP2 | 128 |
| LGALS1 | 190 |
| LSM1 | 97 |
| LYN | 366 |
| MBL2 | 86 |
| PAEP | 72 |
| PPFIA1 | 88 |
| PPFIBP2 | 62 |
| PRKCSH | 77 |
| PTPN6 | 335 |
| PTPRC | 283 |
| PTPRCAP | 60 |
| RASA1 | 218 |
| RNF11 | 156 |
| SEMA4D | 79 |
| SKAP1 | 83 |
| TYK2 | 111 |
| UBC | 7030 |
| UHRF2 | 207 |
| ZAP70 | 252 |
Biological pathways
| Name | # of Products |
|---|---|
| Axon guidance | 739 |
| B cell proliferation | 243 |
| B cell receptor signaling pathway | 217 |
| Defense response to virus | 284 |
| Immunoglobulin biosynthetic process | 61 |
| Negative regulation of cytokine-mediated signaling pathway | 119 |
| Negative regulation of protein kinase activity | 216 |
| Negative regulation of T cell mediated cytotoxicity | 120 |
| Positive regulation of antigen receptor-mediated signaling pathway | 113 |
| Positive regulation of B cell proliferation | 254 |
| Positive regulation of protein kinase activity | 132 |
| Positive regulation of T cell proliferation | 211 |
| Regulation of S phase | 64 |
| Release of sequestered calcium ion into cytosol | 160 |
| T cell differentiation | 128 |
| T cell receptor signaling pathway | 453 |
Biological process
| Name | # of Products |
|---|---|
| Axon guidance | 286 |
| B cell proliferation | 22 |
| B cell receptor signaling pathway | 35 |
| Bone marrow development | 7 |
| Cell surface receptor signaling pathway | 179 |
| Defense response to virus | 72 |
| Dephosphorylation | 39 |
| Hemopoietic progenitor cell differentiation | 18 |
| Immunoglobulin biosynthetic process | 5 |
| Negative regulation of cell adhesion involved in substrate-bound cell migration | 5 |
| Negative regulation of cytokine-mediated signaling pathway | 13 |
| Negative regulation of protein kinase activity | 53 |
| Negative regulation of T cell mediated cytotoxicity | 7 |
| Peptidyl-tyrosine dephosphorylation | 56 |
| Positive regulation of antigen receptor-mediated signaling pathway | 4 |
| Positive regulation of B cell proliferation | 66 |
| Positive regulation of hematopoietic stem cell migration | 3 |
| Positive regulation of protein kinase activity | 36 |
| Positive regulation of stem cell proliferation | 8 |
| Positive regulation of T cell proliferation | 93 |
| Protein dephosphorylation | 88 |
| Regulation of cell cycle | 69 |
| Regulation of S phase | 9 |
| Release of sequestered calcium ion into cytosol | 29 |
| Stem cell development | 12 |
| T cell differentiation | 39 |
| T cell receptor signaling pathway | 90 |
Cellular components
| Name | # of Products |
|---|---|
| External side of plasma membrane | 261 |
| Focal adhesion | 101 |
| Integral to plasma membrane | 817 |
| Membrane raft | 140 |
| Plasma membrane | 2678 |
Protein function
| Name | # of Products |
|---|---|
| Hydrolase activity | 1739 |
| Protein binding | 12191 |
| Protein kinase binding | 1101 |
| Protein tyrosine phosphatase activity | 281 |
| Receptor activity | 3624 |
| Transmembrane receptor protein tyrosine phosphatase activity | 116 |
Diseases
| Name | # of Products |
|---|---|
| Disease mutation | 5332 |
| SCID | 125 |
-
Human CD45RA Antibody : SPRD (OASB01115)Catalog #: OASB01115Conjugation: Spectral Red®Clone: F8-11-13Species Tested: HumanApplication: FC -
Ptprc Antibody - middle region (ARP59108_P050)Catalog #: ARP59108_P050Species Tested: Human, RatApplication: WBFormat: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. -
CD45 Antibody - C-terminal region (OAAB11608)Catalog #: OAAB11608Application: FC,IHC-P,WBFormat: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. -
PTPRC Recombinant Protein (OPCD06515)Catalog #: OPCD06515Conjugation: UnconjugatedApplication: Ctrl (+), SDS-PAGE, WBFormat: Freeze-dried Powder. PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.



